Upcoming Xtalks Webinar: Ligand Binding Assays and Hybrid LC-MS Quantitation of Biotherapeutics and Biomarkers

TORONTO, November 12, 2018 (Newswire.com) - The need to quantitate biotherapeutics has been in demand for a long time. Historically, ligand binding assays have been the method of choice for this measurement. However, as technology has advanced, the use of mass spectrometry has gained a lot of momentum in the last several years. With both quantitation methodologies now available, the obvious question arises, “How do you choose which approach to use: ligand binding assays or mass spectrometry?”

In many cases, either technology can answer the question, but there are definitely times when one technology has advantages over the other.

This live webinar upcoming on Monday, Dec. 3, 2018, at 1 p.m. EST will give an overview of each approach and discuss the types of questions (such as “what reagents are available?”) that will help guide attendees to choose the most appropriate technology. Featured speakers Dawn Dufield and Franklin Spriggs, Directors of BioPharma Services at KCAS Bioanalytical & Biomarker Services, will discuss the most common assay platforms for ligand binding assays as well as each platform’s limitations.

This webinar will also explore reagent needs that will help ensure specificity and adequate sensitivity of the method, as well as some sample preparation techniques that may be useful for both the liquid chromatography-mass spectrometry (LC-MS) and ligand binding assay technologies.

In addition, the speakers will discuss and highlight various approaches for using immunoaffinity LC-MS or hybrid LC-MS, from enrichment at the protein level to enrichment at the peptide level using either bead-based or column-based enrichment strategies. They will also give examples or case studies of where each technology was applied successfully and where they had to make a switch due to some assay issue. Unfortunately, many people choose their quantitative approach based on their capabilities (i.e., a mass spectrometry lab will do hybrid LC-MS and a ligand binding assay lab will do ligand binding assays). However, in some cases, the feasibility of both technologies can initially be considered before a final decision is made. KCAS has deep expertise in both areas and can help to guide and ensure the best approach is chosen to answer the question.

For more information about this complimentary event, visit Ligand Binding Assays and Hybrid LC-MS Quantitation of Biotherapeutics and Biomarkers.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com.

For information about hosting a webinar, visit http://xtalks.com/why-host-a-webinar/.

Contact:

Nima Rajan
Tel: +1 (416) 977-6555 ext 352
Email: [email protected]

Source: Xtalks